Options are subject to the following vesting conditions:
(a) when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase
2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
(b) when the Company executes a partnering transaction for trofinetide outside North America, or submits a Marketing
Authorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
(c) on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.
If we can pass those hurdles, $8+ for sure.
Ann: Notification regarding unquoted securities - NEU, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |